Recent Finacing
Recent Raise
Ducentis BioTherapeutics is a pre-clinical biotech developing CD200/CD200R-targeting molecules to modulate myeloid-driven immune responses and advance candidates toward first‑in‑human trials for autoimmune and inflammatory diseases.
